• Biodegradable Polyesters for VEGF mRNA Delivery in CLI

  2026-09-20

  The reference study develops arginine- and lysine-functionalized three-armed biodegradable polyesters as alternatives to conventional cationic lipids for VEGF mRNA delivery in critical limb ischemia. Its most important contribution is the integration of mRNA transfection, biodegradability, reactive oxygen species scavenging, and nitric oxide release within one lipid nanoparticle platform.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-09-19

  Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 can overcome a major limitation of CDK4/6 inhibition in pancreatic ductal adenocarcinoma: enhanced migration, invasion, and epithelial-to-mesenchymal transition. The study links this response to GSK3β-mediated Wnt/β-catenin activation and provides preclinical evidence for coordinated control of cell-cycle and transcriptional signaling.

• Jasplakinolide: From Actin Control to Translation

  2026-09-18

  Jasplakinolide is more than a cytoskeletal perturbant: its dual ability to induce actin polymerization and stabilize F-actin creates a controllable framework for mechanistic discovery, assay development, and translational decision-making.

• Cimetidine in BBB and Cancer Research

  2026-09-18

  Cimetidine supports mechanism-aware studies that connect H2 receptor biology with reproducible barrier-transport workflows. This guide shows how to use it alongside LLC-PK1-MOCK/MDR1 assays, recovery analysis, and lysosomal-trapping controls without mistaking a pharmacological probe for a validated BBB positive control.

• Ertugliflozin and Tau in Brain Insulin Resistance

  2026-09-17

  This study evaluates ertugliflozin in an intracerebroventricular streptozotocin rat model and links improved cognition with reduced hippocampal tau hyperphosphorylation. Its main contribution is a mechanistic framework connecting disrupted IRS-1/Akt/GSK3β signaling with cholinergic, mitochondrial, apoptotic, and synaptic abnormalities.

• Viral RIPK3 Degradation and Neddylation Biology

  2026-09-17

  Liu and colleagues identified a viral inducer of RIPK3 degradation, or vIRD, that links orthopoxvirus immune evasion to the host SCF ubiquitin-ligase machinery. The study shows that viral control of RIPK3-dependent necroptosis can alter inflammation, replication, and disease severity, providing a mechanistic framework for examining neddylation-dependent protein degradation in infection and cancer biology research.

• From Metabolic Mechanism to qPCR Confidence

  2026-09-16

  The dAGE-exposed mouse study of myriocin illustrates how metabolic phenotypes become translationally useful only when pathway-level measurements are specific, reproducible, and biologically coherent. This article connects AMPK–PGC1α signaling, hepatic lipid regulation, adipose thermogenesis, and qPCR assay strategy, showing how HotStart™ 2X Green qPCR Master Mix can support real-time PCR gene expression analysis, RNA-seq validation, and nucleic acid quantification while preserving appropriate scientific caution.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-09-16

  This scenario-based guide explains how HotStart™ 2X Green qPCR Master Mix, SKU K1070, can support reproducible gene-expression measurements alongside cell viability, proliferation, and cytotoxicity assays. It covers assay compatibility, hot-start specificity, protocol controls, interpretation, and practical supplier selection.

• HotStart™ 2X Green qPCR Master Mix Guide

  2026-09-15

  HotStart™ 2X Green qPCR Master Mix provides a SYBR Green format for real-time amplification of cDNA or DNA while using antibody-mediated Taq polymerase hot-start inhibition to help limit early nonspecific products. It is suitable for gene expression, RNA-seq validation, and nucleic acid quantification, but assay-specific cycling conditions, primer performance, and melt-curve specificity must be validated in the user’s system.

• Reactive Oxygen Species Assay Kit Workflow

  2026-09-15

  Build a reproducible live-cell ROS workflow with DCFH-DA, positive-control validation, and normalization strategies. The assay is especially useful for connecting treatment-induced oxidative stress with apoptosis, DNA damage, and FLASH-radiotherapy sensitization studies.

• DNase I (RNase-free) for Assay Reliability

  2026-09-14

  This scenario-driven guide shows how DNase I (RNase-free), SKU K1088, can reduce DNA-related confounding in RNA, RT-PCR, transcription, and cancer-cell assay workflows. It connects practical controls with evidence from colorectal cancer resistance research while distinguishing documented product features from laboratory recommendations.

• Tacrolimus (FK506) in Immunometabolic Assays

  2026-09-14

  Tacrolimus (FK506) is more than a calcineurin inhibitor: it can serve as a precise perturbation tool for separating cytokine signaling from metabolic-stress responses. This article connects FK506 assay design with AMPK–SQSTM1 biology while defining practical controls, dosing logic, and experimental limitations.

• Salvianolic Acid B and LH2 in Pulmonary Fibrosis

  2026-09-13

  The reference study identifies Salvianolic acid B, also known as Dan Shen Suan B, as a candidate antifibrotic compound that reduces LH2-associated collagen remodeling in pulmonary fibrosis models. Its integrated cellular and tissue-level design links LH2 expression with epithelial–mesenchymal transition, fibroblast activation, Wnt/β-catenin signaling, collagen deposition, and lung architecture, while also highlighting the need for further target-engagement and translational studies.

• GANT61: Practical GLI Inhibition Workflows

  2026-09-12

  GANT61 is a selective GLI inhibitor for connecting Hedgehog pathway output with cancer-cell phenotypes, including transcriptional control, chemotherapy response, and ferroptosis-related assays. This workflow-focused guide shows how to prepare the compound, design concentration and time-course studies, and interpret GLI2–PRDX1 findings without overstating pathway specificity.

• A-1331852: A Precision BCL-XL Inhibitor Workflow

  2026-09-12

  A-1331852 is a selective BCL-XL inhibitor for connecting target engagement with apoptosis, senescence elimination, and combination cancer research. This practical guide translates published BH3-mimetic findings into assay design, dosing, controls, and troubleshooting while clearly separating established evidence from workflow recommendations.

8668 records 1/578 page Next 12345 下5页 Last page